A Registry Study of Biomarkers in Heart Failure

Beijing Institute of Heart, Lung and Blood Vessel Diseases1 site in 1 country5,000 target enrollmentJune 2016

ConditionsCardiovascular Diseases

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Cardiovascular Diseases
Sponsor: Beijing Institute of Heart, Lung and Blood Vessel Diseases
Enrollment: 5000
Locations: 1
Primary Endpoint: Number of death (all cause)
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The registry study aims to discover the prognostic value of bio-markers in heart failure

Detailed Description

The purpose of this study is to investigate the prognostic value of biomarkers in Heart Failure.Patients with confirmed diagnosis of heart failure are enrolled.The primary outcome is all-cause mortality based on the death certificates. The secondary outcome is readmission for heart failure and all-cause mortality/readmission for heart failure according to the patients' medical records.

Registry

clinicaltrials.gov

Start Date

June 2016

End Date

June 2024

Last Updated

7 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Beijing Institute of Heart, Lung and Blood Vessel Diseases

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age greater than or equal to 18 years at the time of admission to the hospital
•With symptoms of new-onset or worsening heart failure
•Received or is eligible to receive a principal hospital discharge diagnosis of HF
•With signs and syndromes as follows: dyspnea at rest or with minimal exertion (dyspnea, orthopnea, or edema)；Rales, peripheral edema, ascites, or pulmonary vascular congestion on chest radiography.
•Patients who received packed red blood cells, whole blood, or platelets less than 10 days before the blood sample was taken;

Exclusion Criteria

•Have objective evidence of cardiac dysfunction documented either by plasma concentrations of BNP and/or N-terminal pro-brain natriuretic peptide (NT-proBNP) \<35 pg/mL or \<125 pg/ml, respectively
•Current known inability to follow instructions or comply with follow-up procedures.
•Eligible patients without informed consent form

Outcomes

Primary Outcomes

Number of death (all cause)

Time Frame: 2 years of follow-up

Number of death within 2 years of discharge

Secondary Outcomes

Number of rehospitalizations for acute heart failure (HF)(2 years of follow-up)
Number of death ( all cause) or readmission for heart failure(2 years of follow-up)